Penumbra (PEN) Cash & Current Investments (2014 - 2026)
Penumbra's (PEN) quarterly Cash & Current Investments came in at $615.7 million in Q1 2026, up 62.51% year-on-year from $378.8 million in Q1 2025, and up 13.0% on a QoQ basis from $544.8 million in Q4 2025.
Penumbra (PEN) Cash & Current Investments (2014 - 2026) Analysis & Trends
Penumbra (PEN) has 13 years of Cash & Current Investments data on file, last reported at $615.7 million in Q1 2026.
- On a quarterly basis, Cash & Current Investments rose 62.51% year-over-year to $615.7 million in Q1 2026; TTM through Mar 2026 was $615.7 million, a 62.51% increase from a year earlier, with the FY2025 full-year figure at $544.8 million, up 60.18% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $615.7 million, up from $544.8 million in the prior quarter.
- Over the last five years, Cash & Current Investments for PEN reached as high as $615.7 million in Q1 2026 and fell as low as $184.4 million in Q3 2022.
- Historically, Cash & Current Investments has averaged $323.2 million across 5 years, with a median of $291.0 million in 2024.
- Across the five-year window, Cash & Current Investments plunged 30.91% in 2022 and soared 62.51% in 2026, its largest moves.
- Year by year, Cash & Current Investments stood at $188.0 million in 2022, then surged by 53.8% to $289.2 million in 2023, then grew by 17.62% to $340.1 million in 2024, then soared by 60.18% to $544.8 million in 2025, then grew by 13.0% to $615.7 million in 2026.
- Per Business Quant data, the three most recent Cash & Current Investments figures were $615.7 million in Q1 2026, $544.8 million in Q4 2025, and $470.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.48 Bn | 176.19 Bn | 6.27 Bn | 7.30 Bn |
| 2 | Stryker | 129.11 Bn | 126.23 Bn | 3.81 Bn | 2.88 Bn |
| 3 | Medtronic | 108.35 Bn | 99.13 Bn | 6.41 Bn | 9.22 Bn |
| 4 | Boston Scientific | 68.68 Bn | 67.22 Bn | 3.61 Bn | 1.45 Bn |
| 5 | Edwards Lifesciences | 48.35 Bn | 44.67 Bn | 1.29 Bn | 3.67 Bn |
| 6 | Dexcom | 28.38 Bn | 27.26 Bn | 750.30 Mn | 1.12 Bn |
| 7 | GE HealthCare Technologies | 28.04 Bn | 25.76 Bn | 1.98 Bn | 2.29 Bn |
| 8 | Smith & Nephew | 26.92 Bn | 26.35 Bn | - | 577.00 Mn |
| 9 | Koninklijke Philips | 24.06 Bn | 20.93 Bn | 2.07 Bn | 3.12 Bn |
| 10 | Penumbra | 12.58 Bn | 11.97 Bn | 253.41 Mn | 615.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 615.66 Mn |
| Dec 31, 2025 | 544.82 Mn |
| Sep 30, 2025 | 470.30 Mn |
| Jun 30, 2025 | 424.56 Mn |
| Mar 31, 2025 | 378.85 Mn |
| Dec 31, 2024 | 340.13 Mn |
| Sep 30, 2024 | 291.02 Mn |
| Jun 30, 2024 | 339.70 Mn |
| Mar 31, 2024 | 313.47 Mn |
| Dec 31, 2023 | 289.19 Mn |
| Sep 30, 2023 | 248.86 Mn |
| Jun 30, 2023 | 221.06 Mn |
| Mar 31, 2023 | 199.10 Mn |
| Dec 31, 2022 | 188.03 Mn |
| Sep 30, 2022 | 184.43 Mn |
| Jun 30, 2022 | 204.37 Mn |
| Mar 31, 2022 | 240.34 Mn |
| Dec 31, 2021 | 254.88 Mn |
| Sep 30, 2021 | 266.93 Mn |
| Jun 30, 2021 | 156.72 Mn |